384 related articles for article (PubMed ID: 26812075)
1. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
2. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
4. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
Adorini L; Pruzanski M; Shapiro D
Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
[TBL] [Abstract][Full Text] [Related]
5. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease.
Aguilar-Olivos NE; Carrillo-Córdova D; Oria-Hernández J; Sánchez-Valle V; Ponciano-Rodríguez G; Ramírez-Jaramillo M; Chablé-Montero F; Chávez-Tapia NC; Uribe M; Méndez-Sánchez N
Ann Hepatol; 2015; 14(4):487-93. PubMed ID: 26019035
[TBL] [Abstract][Full Text] [Related]
6. FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.
Papazyan R; Liu X; Liu J; Dong B; Plummer EM; Lewis RD; Roth JD; Young MA
J Lipid Res; 2018 Jun; 59(6):982-993. PubMed ID: 29559521
[TBL] [Abstract][Full Text] [Related]
7. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.
Vignozzi L; Filippi S; Comeglio P; Cellai I; Sarchielli E; Morelli A; Rastrelli G; Maneschi E; Galli A; Vannelli GB; Saad F; Mannucci E; Adorini L; Maggi M
Mol Cell Endocrinol; 2014 Mar; 384(1-2):143-54. PubMed ID: 24486698
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the mouse organic solute transporter alpha-beta, Ostalpha-Ostbeta, by bile acids.
Frankenberg T; Rao A; Chen F; Haywood J; Shneider BL; Dawson PA
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G912-22. PubMed ID: 16357058
[TBL] [Abstract][Full Text] [Related]
10. A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor.
Narayanan AK; Surendran S; Balakrishnan D; Gopalakrishnan U; Malick S; Valsan A; Philips CA; Watson CJE
Curr Rev Clin Exp Pharmacol; 2024; 19(3):225-233. PubMed ID: 38708917
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy.
Xing X; Burgermeister E; Geisler F; Einwächter H; Fan L; Hiber M; Rauser S; Walch A; Röcken C; Ebeling M; Wright MB; Schmid RM; Ebert MP
Hepatology; 2009 Mar; 49(3):979-88. PubMed ID: 19072826
[TBL] [Abstract][Full Text] [Related]
12. FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH.
Di Pasqua LG; Cagna M; Palladini G; Croce AC; Cadamuro M; Fabris L; Perlini S; Adorini L; Ferrigno A; Vairetti M
Liver Int; 2024 Jan; 44(1):214-227. PubMed ID: 37904642
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition.
Renga B; Mencarelli A; D'Amore C; Cipriani S; Baldelli F; Zampella A; Distrutti E; Fiorucci S
FASEB J; 2012 Jul; 26(7):3021-31. PubMed ID: 22447981
[TBL] [Abstract][Full Text] [Related]
14. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.
Wang K; Zhang Y; Wang G; Hao H; Wang H
Med Res Rev; 2024 Mar; 44(2):568-586. PubMed ID: 37899676
[TBL] [Abstract][Full Text] [Related]
15. FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet.
Singh AB; Dong B; Kraemer FB; Liu J
Physiol Rep; 2020 Mar; 8(5):e14387. PubMed ID: 32170842
[TBL] [Abstract][Full Text] [Related]
16. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J
Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813
[TBL] [Abstract][Full Text] [Related]
17. The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors.
Ricketts ML; Boekschoten MV; Kreeft AJ; Hooiveld GJ; Moen CJ; Müller M; Frants RR; Kasanmoentalib S; Post SM; Princen HM; Porter JG; Katan MB; Hofker MH; Moore DD
Mol Endocrinol; 2007 Jul; 21(7):1603-16. PubMed ID: 17456796
[TBL] [Abstract][Full Text] [Related]
18. Farnesoid X receptor up-regulates expression of lipid transfer inhibitor protein in liver cells and mice.
Li L; Liu H; Peng J; Wang Y; Zhang Y; Dong J; Liu X; Guo D; Jiang Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):880-5. PubMed ID: 24211198
[TBL] [Abstract][Full Text] [Related]
19. Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes.
McIlvride S; Nikolova V; Fan HM; McDonald JAK; Wahlström A; Bellafante E; Jansen E; Adorini L; Shapiro D; Jones P; Marchesi JR; Marschall HU; Williamson C
Am J Physiol Endocrinol Metab; 2019 Aug; 317(2):E399-E410. PubMed ID: 31237448
[TBL] [Abstract][Full Text] [Related]
20. Obeticholic acid attenuates the intestinal barrier disruption in a rat model of short bowel syndrome.
Hou L; Wang H; Yan M; Cai Y; Zheng R; Ma Y; Tang W; Jiang W
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167221. PubMed ID: 38718845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
